Innovative retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Preliminary clinical trials have revealed substantial decreases in physical weight and gains in physiological markers for people with excess weight . Experts believe this novel approach co